Related Experiment Video
Updated: May 11, 2026
08:50
Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy
Z Sungur Ulke1, A Yavru, E Camci
1Department of Anaesthesiology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.
Acta Anaesthesiologica Scandinavica
|May 18, 2013
Summary
Rocuronium-sugammadex safely reversed neuromuscular blockade in myasthenic patients undergoing surgery. This combination offers a viable option for myasthenic patients requiring neuromuscular blockade during procedures.
Area of Science:
- Anesthesiology
- Neuromuscular Pharmacology
Background:
- Neuromuscular blocking agents (NMBAs) use is debated in myasthenia gravis (MG) patients.
- Sugammadex, a selective antagonist, may enable safer NMBA use.
Purpose of the Study:
- Evaluate rocuronium-sugammadex efficacy in myasthenic patients during thoracoscopic thymectomy.
Main Methods:
- 10 MG patients received 0.3 mg/kg rocuronium for neuromuscular block.
- Sugammadex (2 mg/kg) reversed the block post-surgery.
- Recovery time (TOF > 0.9) was measured.
Main Results:
- All patients were extubated successfully in the operating room.
- Mean recovery time after sugammadex was 111 seconds.
- Rocuronium dose averaged 48 mg for a 62-minute surgery.
Conclusions:
- Rocuronium-sugammadex facilitates rapid neuromuscular function recovery in MG patients.
- This combination is a rational choice for MG patients needing neuromuscular blockade during surgery.
Related Concept Videos
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...